Researchers have determined that two prevalent drug therapies — rifaximin and lubiprostone — offer some of the best options for treating irritable bowel syndrome, a widespread disorder that affects up to one in five Americans. The findings are based on an analysis of more than two dozen large-scale clinical trials.